Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10273MR)

This product GTTS-WQ10273MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10273MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5041MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ8854MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ3906MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ2889MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ1364MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ1563MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13948MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ4266MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW